Stock comparison
Medpace Holdings
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MEDP
Medpace Holdings
Market cap
$11.86B
Sector
Healthcare
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
Overall winner
Medpace Holdings MEDP
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MEDP | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 53C | 64C | RMD |
| Benjamin Graham | 59C | 67B | RMD |
| Philip Fisher | 62C | 67B | RMD |
| Peter Lynch | 57C | 50C | MEDP |
| Joel Greenblatt | 71B | 39D | MEDP |
| Charlie Munger | 59C | 61C | RMD |
| Terry Smith | 67B | 65B | MEDP |
Side-by-side metrics
| Metric | MEDP | RMD |
|---|---|---|
| Market cap | $11.86B | $29.57B |
| P/E (TTM) | 25.7x | 19.6x |
| EV/EBIT | 21.2x | 17.1x |
| ROIC (TTM) | 56.06% | 19.63% |
| Gross margin | 29.07% | 61.69% |
| Net margin | 17.19% | 27.44% |
| Revenue CAGR 5y | 21.99% | 12.64% |
| EPS CAGR 5y | 32.59% | 30.73% |
| Debt / Equity | 0.2x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MEDP leads on
- ROIC (TTM)56.06%vs 19.63%+65%
- Revenue CAGR 5y21.99%vs 12.64%+43%
- EPS CAGR 5y32.59%vs 30.73%+6%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$29.57Bvs $11.86B+60%
- Gross margin61.69%vs 29.07%+53%
- Debt / Equity0.1xvs 0.2x+47%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.